Spero Therapeutics (SPRO) Accounts Payables (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Accounts Payables data on file, last reported at $217000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 87.71% year-over-year to $217000.0; the trailing twelve-month figure through Mar 2026 stood at $217000.0 (down 87.71% YoY), and the FY2025 full-year result was $693000.0, down 90.51% from the prior year.
• Accounts Payables for Q1 2026 stood at $217000.0, down from $693000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $7.3 million in Q4 2024 and bottomed at $217000.0 in Q1 2026.
• The 5-year median for Accounts Payables is $1.4 million (2025), against an average of $2.2 million.
• The widest annual swing landed in 2024, when Accounts Payables surged 452.13%; it then tumbled 90.51% in 2025.
• A 5-year view of Accounts Payables shows it stood at $617000.0 in 2022, then jumped by 123.34% to $1.4 million in 2023, then surged by 430.19% to $7.3 million in 2024, then plunged by 90.51% to $693000.0 in 2025, then plunged by 68.69% to $217000.0 in 2026.
• The last three Accounts Payables figures came in at $217000.0 (Q1 2026), $693000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.

Peer Comparison